<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38499155</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-820X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Virologica Sinica</Title><ISOAbbreviation>Virol Sin</ISOAbbreviation></Journal><ArticleTitle>Integration of HiBiT into enteroviruses: A universal tool for advancing enterovirus virology research.</ArticleTitle><Pagination><StartPage>422</StartPage><EndPage>433</EndPage><MedlinePgn>422-433</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virs.2024.03.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1995-820X(24)00030-0</ELocationID><Abstract><AbstractText>The utilization of enteroviruses engineered with reporter genes serves as a valuable tool for advancing our understanding of enterovirus biology and its applications, enabling the development of effective therapeutic and preventive strategies. In this study, our initial attempts to introduce a NanoLuc luciferase (NLuc) reporter gene into recombinant enteroviruses were unsuccessful in rescuing viable progenies. We hypothesized that the size of the inserted tag might be a determining factor in the rescue of the virus. Therefore, we inserted the 11-amino-acid HiBiT tag into the genomes of enterovirus A71 (EV-A71), coxsackievirus A10 (CVA10), coxsackievirus A7 (CVA7), coxsackievirus A16 (CVA16), namely EV-A71-HiBiT, CVA16-HiBiT, CVA10-HiBiT, CVA7-HiBiT, and observed that the HiBiT-tagged viruses exhibited remarkably high rescue efficiency. Notably, the HiBiT-tagged enteroviruses displayed comparable characteristics to the wild-type viruses. A direct comparison between CVA16-NLuc and CVA16-HiBiT recombinant viruses revealed that the tiny HiBiT insertion had minimal impact on virus infectivity and replication kinetics. Moreover, these HiBiT-tagged enteroviruses demonstrated high genetic stability in different cell lines over multiple passages. In addition, the HiBiT-tagged viruses were successfully tested in antiviral drug assays, and the sensitivity of the viruses to drugs was not affected by the HiBiT tag. Ultimately, our findings provide definitive evidence that the integration of HiBiT into enteroviruses presents a universal, convenient, and invaluable method for advancing research in the realm of enterovirus virology. Furthermore, HiBiT-tagged enteroviruses exhibit great potential for diverse applications, including the development of antivirals and the elucidation of viral infection mechanisms.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Publishing services by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Medicine, Shanghai University, Shanghai, 200444, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaohong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Medicine, Shanghai University, Shanghai, 200444, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Guangzhou Institutes of Biomedicine and Health, The Chinese Academy of Sciences, Guangzhou, 510530, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Minghao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jitong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chenli Qiu</LastName><AffiliationInfo><Affiliation>Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, 200433, China; Shanghai Geriatric Medical Center, Shanghai, 201104, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shu</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Center for Biotherapy, Zhongshan Hospital/Zhongshan Hospital (Xiamen), Fudan University, 361015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miaomiao Kang</LastName><AffiliationInfo><Affiliation>Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. Electronic address: zhangxiaoyan@fudan.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jianqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. Electronic address: xujianqing@fudan.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shuye</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine, Shanghai University, Shanghai, 200444, China; Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. Electronic address: shuye_zhang@fudan.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virol Sin</MedlineTA><NlmUniqueID>101514185</NlmUniqueID><ISSNLinking>1995-820X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.13.12.-</RegistryNumber><NameOfSubstance UI="D008156">Luciferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="Y">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="N">Genome, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014773" MajorTopicYN="N">Virology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drug screening</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Infectious clones</Keyword><Keyword MajorTopicYN="N">Luciferase</Keyword><Keyword MajorTopicYN="N">Reporter genes</Keyword></KeywordList><CoiStatement>Conflict of interest The research was conducted in the absence of any commercial or financial relationships. The authors declare that they have no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>2</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>19</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>18</Day><Hour>20</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38499155</ArticleId><ArticleId IdType="pmc">PMC11279724</ArticleId><ArticleId IdType="doi">10.1016/j.virs.2024.03.004</ArticleId><ArticleId IdType="pii">S1995-820X(24)00030-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnold G.F., Resnick D.A., Smith A.D., Geisler S.C., Holmes A.K., Arnold E. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Intervirology. 1996;39:72–78.</Citation><ArticleIdList><ArticleId IdType="pubmed">8957672</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J.M., Qu M., Liu H.T., Wan X., Li F., Hou A., Zhou Y., Sun B., Cai L.J., Su W.H., Jiang C.L. Myristoylation of EV71 VP4 is essential for infectivity and interaction with membrane structure. Virol. Sin. 2020;35:599–613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736455</ArticleId><ArticleId IdType="pubmed">32399947</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.K., Li X.H., Wang M., Li Y., Fan J., Yan J.J., Zhang S.Y., Lu L., Zou P. A cysteine protease inhibitor GC376 displays potent antiviral activity against coxsackievirus infection. Curr. Res. Microb. Sci. 2023;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10520345</ArticleId><ArticleId IdType="pubmed">37767059</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu W.Y., Lo Y.H., Yeh T.C. Coxsackievirus associated hand, foot and mouth disease in an adult. QJM. 2016;109:823–824.</Citation><ArticleIdList><ArticleId IdType="pubmed">27634973</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A.H., Liu C.C., Chang J.Y., Jiang R.N., Hsieh Y.C., Tsao A., Wu C.L., Huang J.L., Fung C.P., Hsieh S.M., Wang Y.F., Wang J.R., Hu M.H., Chiang J.R., Su I.J., Chong P.C.S. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One. 2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu J.Q., Lee Y.J., Park J.N., Kim S.M., Lee K.N., Ko Y.J., Lee H.S., Cho I.S., Kim B., Park J.H. Construction of a bovine enterovirus-based vector expressing a foot-and-mouth disease virus epitope. J. Virol. Methods. 2013;189:101–104.</Citation><ArticleIdList><ArticleId IdType="pubmed">23391822</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua K.B., Ng Q., Meng T., Jia Q. Development of stable, cold-adapted, temperature-sensitive/conditional lethal chimeric enterovirus A71 and coxsackievirus A16. Virol. Sin. 2022;37:769–773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9583105</ArticleId><ArticleId IdType="pubmed">35964922</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C.L., Li X.D., Liu S.Q., Xu L.L., Ye H.Q., Qin C.F., Zhang B. Development and characterization of a clinical strain of Coxsackievirus A16 and an eGFP infectious clone. Virol. Sin. 2015;30:269–276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8200862</ArticleId><ArticleId IdType="pubmed">26220729</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q.Q., Yuan S.L., Zhang C., Wang Y., Wang Y.Z., He G.M., Zhang S.Y., Altmeyer R., Zou G. Discovery of itraconazole with broad-spectrum, antienterovirus activity that targets nonstructural protein 3A. Antimicrob. Agents Chemother. 2015;59:2654–2665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="pubmed">25691649</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspar N., Zambito G., Dautzenberg I.J.C., Cramer S.J., Hoeben R.C., Lowik C., Walker J.R., Kirkland T.A., Smith T.P., Van Weerden W.M., De Vrij J., Mezzanotte L. NanoBiT system and hydrofurimazine for optimized detection of viral infection in mice-a novel in vivo imaging platform. Int. J. Mol. Sci. 2020;21:5863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7461499</ArticleId><ArticleId IdType="pubmed">32824188</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashem S.M., Gad M.K., Anwar H.M., Saleh N.M., Shamma R.N., Elsherif N.I. Itraconazole-loaded ufasomes: evaluation, characterization, and anti-fungal activity against. Pharmaceutics. 2023;15:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9862016</ArticleId><ArticleId IdType="pubmed">36678655</ArticleId></ArticleIdList></Reference><Reference><Citation>Jubelt B., Lipton H.L. Enterovirus/picornavirus infections. Handb. Clin. Neurol. 2014;123:379–416.</Citation><ArticleIdList><ArticleId IdType="pubmed">25015496</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C., Kang H., Kim D.E., Song J.H., Choi M., Kang M., Lee K., Kim H.S., Shin J.S., Jeong H., Jung S., Han S.B., Kim J.H., Ko H.J., Lee C.K., Kim M., Cho S. Antiviral activity of micafungin against enterovirus 71. Virol. J. 2016;13:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4907259</ArticleId><ArticleId IdType="pubmed">27296985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimmis B.D., Downing C., Tyring S. Hand-foot-and-mouth disease caused by coxsackievirus A6 on the rise. Cutis. 2018;102:353–356.</Citation><ArticleIdList><ArticleId IdType="pubmed">30566537</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X.Y., Zhu Q.C., Liang J.Q., Liu S.Y., Liu D.X., Fung T.S. Development of HiBiT-tagged recombinant infectious bronchitis coronavirus for efficient and viral quantification. Front. Microbiol. 2020;11:2100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7485224</ArticleId><ArticleId IdType="pubmed">32983065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K., Wang G.C., He Y.L., Han J.F., Ye Q., Qin C.F., Chen R. Crystal structures of enterovirus 71 (EV71) recombinant virus particles provide insights into vaccine design. J. Biol. Chem. 2015;290:3198–3208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4318995</ArticleId><ArticleId IdType="pubmed">25492868</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakawa K., Jeremiah S.S., Ohtake N., Matsunaga S., Yamaoka Y., Nishi M., Morita T., Saji R., Nishii M., Kimura H., Hasegawa H., Takeuchi I., Ryo A. Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles. J. Mol. Cell Biol. 2020;12:987–990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543420</ArticleId><ArticleId IdType="pubmed">32931563</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagashima S., Primadharsini P.P., Nishiyama T., Takahashi M., Murata K., Okamoto H. Development of a HiBiT-tagged reporter hepatitis E virus and its utility as an antiviral drug screening platform. J. Virol. 2023;97</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10537679</ArticleId><ArticleId IdType="pubmed">37681960</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P.J., Zheng Y.M., Wang W.Q., Hong L.P., Delpeyroux F., Arenzana-Seisdedos F., Altmeyer R. Suramin interacts with the positively charged region surrounding the 5-fold axis of the EV-A71 capsid and inhibits multiple enterovirus A. Sci. Rep. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5317167</ArticleId><ArticleId IdType="pubmed">28218309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P.J., Zou G., Bailly B., Xu S.S., Zeng M., Chen X.S., Shen L., Zhang Y., Guillon P., Arenzana-Seisdedos F., Buchy P., Li J., Von Itzstein M., Li Q.H., Altmeyer R. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo. Emerg. Microbes Infect. 2014;3:e62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185360</ArticleId><ArticleId IdType="pubmed">26038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei R., Surendran A., Singaravelu R., Jamieson T.R., Taklifi P., Poutou J., Azad T., Ilkow C.S. Detection of SARS-CoV-2 receptor-binding domain antibody using a HiBiT-based bioreporter. J. Vis. Exp. 2021;174</Citation><ArticleIdList><ArticleId IdType="pubmed">34459810</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarma N. Hand, foot, and mouth disease: current scenario and Indian perspective. Indian J. Dermatol. Venereol. Leprol. 2013;79:165–175.</Citation><ArticleIdList><ArticleId IdType="pubmed">23442455</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang B.D., Deng C.L., Ye H.G., Xu W.B., Yuan Z.M., Shi P.Y., Zhang B. Development and characterization of a stable eGFP enterovirus 71 for antiviral screening. Antivir. Res. 2013;97:198–205.</Citation><ArticleIdList><ArticleId IdType="pubmed">23267829</ArticleId></ArticleIdList></Reference><Reference><Citation>Shribman A.J., Hanning C.D. Hyperbaric bupivacaine and hyperbaric cinchocaine: a comparison of their use for spinal anaesthesia. Eur. J. Anaesthesiol. 1986;3:103–110.</Citation><ArticleIdList><ArticleId IdType="pubmed">2430797</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmonds P., Gorbalenya A.E., Harvala H., Hovi T., Knowles N.J., Lindberg A.M., Oberste M.S., Palmenberg A.C., Reuter G., Skern T., Tapparel C., Wolthers K.C., Woo P.C.Y., Zell R. Recommendations for the nomenclature of enteroviruses and rhinoviruses. Arch. Virol. 2020;165:793–797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7024059</ArticleId><ArticleId IdType="pubmed">31980941</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair W., Omar M. StatPearls; Treasure Island (FL): 2023. Enterovirus.</Citation></Reference><Reference><Citation>Strating J.R.P.M., Van Der Linden L., Albulescu L., Bigay J., Arita M., Delang L., Leyssen P., Van Der Schaar H.M., Lanke K.H.W., Thibaut H.J., Ulferts R., Drin G., Schlinck N., Wubbolts R.W., Sever N., Head S.A., Liu J.O., Beachy P.A., De Matteis M.A., Shair M.D., Olkkonen V.M., Neyts J., Van Kuppeveld F.J.M. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep. 2015;10:600–615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383725</ArticleId><ArticleId IdType="pubmed">25640182</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumiyadorj A., Murai K., Shimakami T., Kukroki K., Nishikawa T., Kakuya M., Yamada A., Wang Y., Ishida A., Shirasaki T., Kawase S., Li Y.Y., Okada H., Nio K., Kawaguchi K., Yamashita T., Sakai Y., Duger D., Mizukoshi E., Honda M., Kaneko S. A single hepatitis B virus genome with a reporter allows the entire viral life cycle to be monitored in primary human hepatocytes. Hepatol. Commun. 2022;6:2441–2454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9426382</ArticleId><ArticleId IdType="pubmed">35691027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulferts R., De Boer S.M., Van Der Linden L., Bauer L., Lyoo H.R., Maté M.J., Lichière J., Canard B., Lelieveld D., Omta W., Egan D., Coutard B., Van Kuppeveld F.J.M. Screening of a library of FDA-approved drugs identifies several enterovirus replication inhibitors that target viral protein 2C. Antimicrob. Agents Chemother. 2016;60:2627–2638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4862474</ArticleId><ArticleId IdType="pubmed">26856848</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Schaar H.M., Melia C.E., Van Bruggen J.a.C., Strating J.R.P.M., Van Geenen M.E.D., Koster A.J., Bárcena M., Van Kuppeveld M. Illuminating the sites of enterovirus replication in living cells by using a split-GFP-tagged viral protein. mSphere. 2016;1:e00104–e00116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4935779</ArticleId><ArticleId IdType="pubmed">27390781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Yan J., Zhu L., Wang M., Liu L., Yu R., Chen M., Xun J., Zhang Y., Yi Z., Zhang S. The establishment of infectious clone and single round infectious particles for coxsackievirus A10. Virol. Sin. 2020;35:426–435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462955</ArticleId><ArticleId IdType="pubmed">32144688</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L.L., Shan C., Deng C.L., Li X.D., Shang B.D., Ye H.Q., Liu S.Q., Yuan Z.M., Wang Q.Y., Shi P.Y., Zhang B. Development of a stable luciferase enterovirus 71 reporter virus. J. Virol. Methods. 2015;219:62–66.</Citation><ArticleIdList><ArticleId IdType="pubmed">25843263</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu R., Wang M., Liu L., Yan J., Fan J., Li X., Kang M., Xu J., Zhang X., Zhang S. The development and characterization of a stable Coxsackievirus A16 infectious clone with Nanoluc reporter gene. Front. Microbiol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9871592</ArticleId><ArticleId IdType="pubmed">36704559</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun S.I., Song B.H., Woolley M.E., Frank J.C., Julander J.G., Lee Y.M. Development, characterization, and application of two reporter-expressing recombinant Zika viruses. Viruses. 2020;12:572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7290298</ArticleId><ArticleId IdType="pubmed">32456014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Zhang G., Zhang Y., Lin X., Zhao X., Cui Q., Rong L., Du R. Development of an HiBiT-tagged reporter H3N2 influenza A virus and its utility as an antiviral screening platform. J. Med. Virol. 2023;95</Citation><ArticleIdList><ArticleId IdType="pubmed">36424458</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Li J.X., Jin P.F., Wang Y.X., Zhu F.C. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine. Expert Rev. Vaccines. 2016;15:803–813.</Citation><ArticleIdList><ArticleId IdType="pubmed">27206811</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., Zhang Y.T., Yao X., Chu K., Chen Q.H., Hu Y.M., Wu X., Liu P., Zhu L.Y., Gao F., Jin H., Chen Y.J., Dong Y.Y., Liang Y.C., Shi N.M., Ge H.M., Liu L., Chen S.G., Ai X., Zhang Z.Y., Ji Y.G., Luo F.J., Chen X.Q., Zhang Y., Zhu L.W., Liang Z.L., Shen X.L. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–2032.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>